JPMorgan Chase & Co. restated their overweight rating on shares of Shire PLC (NASDAQ:SHPG) in a report issued on Monday.

A number of other equities research analysts have also issued reports on SHPG. Piper Jaffray Cos. set a $201.00 target price on shares of Shire PLC and gave the stock a hold rating in a report on Saturday, October 1st. Leerink Swann reaffirmed a buy rating on shares of Shire PLC in a report on Saturday, October 1st. Citigroup Inc. reaffirmed a buy rating on shares of Shire PLC in a report on Wednesday, August 3rd. RBC Capital Markets reaffirmed an outperform rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Zacks Investment Research raised shares of Shire PLC from a sell rating to a hold rating in a report on Thursday, August 4th. Five equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. Shire PLC currently has a consensus rating of Buy and a consensus price target of $228.15.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Shire PLC (NASDAQ:SHPG) traded up 2.47% on Monday, reaching $190.37. 252,218 shares of the company traded hands. The stock has a 50 day moving average of $194.54 and a 200-day moving average of $188.15. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The stock has a market capitalization of $56.70 billion, a price-to-earnings ratio of 39.56 and a beta of 1.16.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, topping the consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. During the same quarter in the previous year, the firm earned $2.63 EPS. The firm’s revenue was up 55.9% compared to the same quarter last year. On average, equities analysts anticipate that Shire PLC will post $12.92 EPS for the current year.

The firm also recently announced a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were issued a $0.139 dividend. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 15.63%.

Large investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC increased its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the period. Canal Insurance CO acquired a new stake in Shire PLC during the second quarter worth approximately $102,000. FTB Advisors Inc. increased its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. acquired a new stake in Shire PLC during the second quarter worth approximately $111,000. Finally, Ropes Wealth Advisors LLC acquired a new stake in Shire PLC during the second quarter worth approximately $114,000. 24.30% of the stock is owned by institutional investors.

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.